{"schema_version":"secwatch.filing_event.v1","accession":"0001384101-22-000026","form_type":"8-K","ticker":"VCYT","cik":"0001384101","company_name":"VERACYTE, INC.","filed_at":"2022-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:04:06.235458+00:00","generated_at":"2026-06-27T03:31:17.480286+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Veracyte Q4 2021 revenue $67.3M (+95% YoY); guides 2022 revenue $260-275M","bullets":["Q4 2021 revenue $67.3M (+95% YoY); full-year 2021 revenue $219.5M (+87% YoY).","Net loss $10.5M in Q4 ($0.15 per share); full-year loss $75.6M ($1.11 per share).","Test volume grew to 22,300 in Q4 (+70% YoY); full-year volume 78,565 (+77% YoY).","2022 revenue guidance $260M-$275M, representing 18-25% YoY growth.","Completed acquisitions of Decipher Biosciences and HalioDx; launched Decipher Bladder test."],"urls":{"canonical":"https://secwatch.observer/filing/0001384101-22-000026","json":"https://secwatch.observer/filing/0001384101-22-000026.json","markdown":"https://secwatch.observer/filing/0001384101-22-000026.md","text":"https://secwatch.observer/filing/0001384101-22-000026.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1384101/000138410122000026/0001384101-22-000026-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1384101/000138410122000026/vcyt-20220228.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T03:31:17.480286+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}